scholarly journals Yoga-Based Group Intervention for In-patients With Schizophrenia Spectrum Disorders—A Qualitative Approach

2021 ◽  
Vol 12 ◽  
Author(s):  
Theresa Schulze ◽  
Eric Hahn ◽  
Inge Hahne ◽  
Niklas Bergmann ◽  
Lukas Marian Fuchs ◽  
...  
Keyword(s):  
Group Intervention ◽  
Controlled Trial ◽  
Complementary Therapy ◽  
Diagnostic Interview ◽  
Future Research ◽  
Schizophrenia Spectrum Disorders ◽  
Subjective Experiences ◽  
Structured Interviews ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

Background: Yoga may pose a promising complementary therapy in the multimodal treatment of in-patients with schizophrenia spectrum disorders (SSD). However, to date, no studies have qualitatively examined in-patients' with SSD experiences of Yoga as well as their perceptions of its limitations and benefits as a treatment component. This qualitative study aimed to explore for the first time the mechanisms and processes of Yoga-based Group Intervention (YoGI) for in-patients with SSD in Germany by asking for their subjective experiences. Findings could serve as a preliminary basis for developing an effective and evidence-based YoGI manual tailored to this patient group.Materials and Methods: In total, 25 semi-structured interviews were conducted directly after YoGI, for which responses were either noted down by hand or audio-recorded. The interview guide was pilot-tested and consisted of 14 questions to explore the personal articulated experiences of participation in YoGI from in-patients with SSD. Positive, negative, depressive, and anxiety symptoms were assessed during a diagnostic interview and through questionnaires. The interview data was transcribed, coded by two independent researchers, and analysed using an inductive thematic approach. The research team collaboratively discussed emerging categories to reduce redundancy and form meaningful themes and subthemes.Results: The analysis revealed seven main themes. YoGI was perceived as feasible and focusing on individual adaptation, captured by the theme inclusivity. Nevertheless, participants encountered challenges; thus, physical limitations need to be considered. While practising together, participants experienced interconnectedness and developed a mindful stance as they accepted their limitations and adapted exercises with self-compassion. Patients described that following the flow of the asanas required physical persistence, which ultimately led many participants to experience confidence and relaxation. YoGI affected symptom representation as heightened awareness led participants to notice impeding as well as improved symptoms.Conclusion: YoGI showed various promising effects on in-patients with SSD. Future research should examine to what extent these effects can be sustained and how the mindful approach during YoGI can be transferred to areas outside the Yoga class. Furthermore, a randomised controlled trial could investigate the effectiveness of a manualised YoGI.

scholarly journals Randomised controlled trial of Compensatory Cognitive Training and a Computerised Cognitive Remediation programme

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Frances Dark ◽  
Ellie Newman ◽  
Victoria Gore-Jones ◽  
Veronica De Monte ◽  
Marta I. Garrido ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Randomised Controlled Trial ◽  
Outcome Measures ◽  
Cognitive Training ◽  
Controlled Trial ◽  
Schizophrenia Spectrum Disorders ◽  
Cognitive Interventions ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders ◽  
Randomised Controlled

Abstract Background Compensation and adaptation therapies have been developed to improve community functioning via improving neurocognitive abilities in people with schizophrenia. Various modes of delivering compensation and adaptation therapies have been found to be effective. The aim of this trial is to compare two different cognitive interventions, Compensatory Cognitive Training (CCT) and Computerised Interactive Remediation of Cognition–Training for Schizophrenia (CIRCuiTS). The trial also aims to identify if mismatch negativity (MMN) can predict an individual’s response to the compensation and adaptation programmes. Methods This study will use a randomised, controlled trial of two cognitive interventions to compare the impact of these programmes on measures of neurocognition and function. One hundred clinically stable patients aged between 18 and 65 years with a diagnosis of a schizophrenia spectrum disorder will be recruited. Participants will be randomised to either the CCT or the CIRCuiTS therapy groups. The outcome measures are neurocognition (BACS), subjective sense of cognitive impairment (SSTICS), social functioning (SFS), and MMN (measured by EEG) in people with schizophrenia spectrum disorders. Discussion This trial will determine whether different approaches to addressing the cognitive deficits found in schizophrenia spectrum disorders are of comparable benefit using the outcome measures chosen. This has implications for services where cost and lack of computer technology limit the implementation and dissemination of interventions to address cognitive impairment in routine practice. The trial will contribute to the emerging evidence of MMN as a predictor of response to cognitive interventions. Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12618000161224. Registered on 2 February 2018. Protocol version: 4.0, 18 June 2018.

scholarly journals A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Kristen R Dwyer ◽  
Alexandra M Andrea ◽  
Christina L G Savage ◽  
Ryan D Orth ◽  
LeeAnn Shan ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Self Report ◽  
Schizophrenia Spectrum Disorders ◽  
Social Affiliation ◽  
Subjective Responses ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders ◽  
The Impact

Abstract Prior studies examining the impact of oxytocin on negative symptoms in schizophrenia have yielded mixed results. The current study explored whether oxytocin can improve more proximal indicators of social affiliation as indicated by changes in behavior, language and subjective indices of social affiliation among individuals with schizophrenia spectrum disorders during a role-play designed to elicit affiliative responses. We tested the hypothesis that daily intranasal oxytocin administered for 6 weeks would improve social affiliation as manifested by increased social skill ratings, use of positive, affiliative, and social words, and subjective responses from a previously published randomized controlled trial. Forty outpatients with schizophrenia or schizoaffective disorder were randomized to the oxytocin, galantamine, or placebo group and completed affiliative role-plays and self-report questionnaires of affect, reactions to the affiliative confederate, and willingness to interact at baseline and post-treatment. Results demonstrated that oxytocin was not effective at improving behavioral or subjective indicators of social affiliation. This study adds to a growing literature that the prosocial effects of oxytocin in schizophrenia are limited or null.

scholarly journals Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

2020 ◽  
Vol 46 (6) ◽  
pp. 1396-1408 ◽  
Author(s):  
Pantelis Leptourgos ◽  
Martin Fortier-Davy ◽  
Robin Carhart-Harris ◽  
Philip R Corlett ◽  
David Dupuis ◽  
...  
Keyword(s):  
Brain Imaging ◽  
Working Group ◽  
Future Research ◽  
Schizophrenia Spectrum Disorders ◽  
Drug Induced ◽  
Computational Approaches ◽  
Schizophrenia Spectrum ◽  
Multidisciplinary Working ◽  
Similarities And Differences ◽  
Spectrum Disorders

Abstract The recent renaissance of psychedelic science has reignited interest in the similarity of drug-induced experiences to those more commonly observed in psychiatric contexts such as the schizophrenia-spectrum. This report from a multidisciplinary working group of the International Consortium on Hallucinations Research (ICHR) addresses this issue, putting special emphasis on hallucinatory experiences. We review evidence collected at different scales of understanding, from pharmacology to brain-imaging, phenomenology and anthropology, highlighting similarities and differences between hallucinations under psychedelics and in the schizophrenia-spectrum disorders. Finally, we attempt to integrate these findings using computational approaches and conclude with recommendations for future research.

scholarly journals A randomized-controlled trial of treatment for self-stigma among persons diagnosed with schizophrenia-spectrum disorders

2019 ◽  
Vol 54 (11) ◽  
pp. 1363-1378 ◽  
Author(s):  
Philip T. Yanos ◽  
Paul H. Lysaker ◽  
Steven M. Silverstein ◽  
Beth Vayshenker ◽  
Lauren Gonzales ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Schizophrenia Spectrum Disorders ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals The Effects of Metacognition-Oriented Social Skills Training on Psychosocial Outcome in Schizophrenia-Spectrum Disorders: A Randomized Controlled Trial

2017 ◽  
Vol 44 (6) ◽  
pp. 1235-1244 ◽  
Author(s):  
Felix Inchausti ◽  
Nancy V García-Poveda ◽  
Alejandro Ballesteros-Prados ◽  
Javier Ortuño-Sierra ◽  
Sergio Sánchez-Reales ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Social Skills ◽  
Social Skills Training ◽  
Controlled Trial ◽  
Skills Training ◽  
Psychosocial Outcome ◽  
Schizophrenia Spectrum Disorders ◽  
Randomized Controlled ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

Factor Structure of the Bern Psychopathology Scale in a Sample of Patients with Schizophrenia Spectrum Disorders

2015 ◽  
Vol 30 (7) ◽  
pp. 880-884 ◽  
Author(s):  
Fabian U. Lang ◽  
Annabel S. Stierlin ◽  
Katharina Stegmayer ◽  
Sebastian Walther ◽  
Thomas Becker ◽  
...  
Keyword(s):  
Factor Structure ◽  
University Hospital ◽  
Future Research ◽  
Motor Behaviour ◽  
Schizophrenia Spectrum Disorders ◽  
Longitudinal Assessment ◽  
Symptom Pattern ◽  
Schizophrenia Spectrum ◽  
Binary Division ◽  
Spectrum Disorders

AbstractBackground:The Bern Psychopathology Scale (BPS) is based on a system-specific approach to classifying the psychopathological symptom pattern of schizophrenia. It consists of subscales for three domains (language, affect and motor behaviour) that are hypothesized to be related to specific brain circuits. The aim of the study was to examine the factor structure of the BPS in patients with schizophrenia spectrum disorders.Methods:One hundred and forty-nine inpatients with schizophrenia spectrum disorders were recruited at the Department of Psychiatry II, Ulm University, Germany (n = 100) and at the University Hospital of Psychiatry, Bern, Switzerland (n = 49). Psychopathology was assessed with the BPS. The VARCLUS procedure of SAS® (a type of oblique component analysis) was used for statistical analysis.Results:Six clusters were identified (inhibited language, inhibited motor behaviour, inhibited affect, disinhibited affect, disinhibited language/motor behaviour, inhibited language/motor behaviour) which explained 40.13% of the total variance of the data. A binary division of attributes into an inhibited and disinhibited cluster was appropriate, although an overlap was found between the language and motor behaviour domains. There was a clear distinction between qualitative and quantitative symptoms.Conclusions:The results argue for the validity of the BPS in identifying subsyndromes of schizophrenia spectrum disorders according to a dimensional approach. Future research should address the longitudinal assessment of dimensional psychopathological symptoms and elucidate the underlying neurobiological processes.

Hallucinations without delusions in patients with first-episode psychosis: Clinical correlates and implications for pathophysiological models

2016 ◽  
Vol 33 (S1) ◽  
pp. S32-S32
Author(s):  
I. Melle
Keyword(s):  
Negative Symptoms ◽  
Clinical Symptoms ◽  
Age At Onset ◽  
Diagnostic Interview ◽  
Clinical Profile ◽  
First Episode ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders ◽  
Competing Interest

IntroductionThe symptomatic distribution in schizophrenia spectrum disorder is heterogeneous. Patients may experience hallucinations, delusions and combinations thereof, in addition to disorganized and negative symptoms. We have previously found that patients with monosymptomatic hallucinations exhibited a different clinical profile than patients with monosymptomatic delusions or combinations of the two; with an earlier age at onset and more suicidal symptoms.AimsTo replicate findings in a new group of patients with schizophrenia spectrum disorders.MethodsA total of 421 consecutive patients with schizophrenia spectrum disorders were included into the study. They were comprehensively assessed by specifically trained psychiatrists or clinical psychologists; using the SCID for DSM-IV for diagnostic purposes, the PANSS to assess current clinical symptoms and CDSS to assess current depression. Lifetime presence of different symptom types was ascertained during the diagnostic interview.ResultsA total of 346 (82%) had experienced both hallucinations and delusion, 63 (15%) had experienced delusions without hallucinations, 10 (2.5%) had experienced hallucinations without delusions and 2 patients (0.5%) had neither but experienced negative and severely disorganized symptoms. Contrary to hypothesis, we did not find any statistically significant differences in age at onset and in clinical symptoms (including suicidality) between these groups. We also did not find any differences in the type of hallucinatory experiences between hallucinating groups.ConclusionsIn a new sample of patients, we did not replicate previous findings of a different clinical profile in patients with monosymptomatic hallucinations. This type of psychotic disorder is relatively rare, which might pose a problem concerning statistical strength.Disclosure of interestThe author has not supplied his declaration of competing interest.

Schizophrenia

2014 ◽  
Author(s):  
Alex S. Cohen ◽  
Dallas A. Callaway ◽  
Tracey L. Auster
Keyword(s):  
Depressive Symptoms ◽  
Empirical Investigation ◽  
Cognitive Behavioral ◽  
Future Research ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Treatment Considerations ◽  
Spectrum Disorders ◽  
New Treatments

Depressive symptoms commonly occur in individuals with schizophrenia-spectrum disorders. Empirical investigation of this comorbidity has revealed a number of interesting and potentially confusing findings. The purpose of this review is to summarize this literature, focusing on clinical, cognitive, behavioral, phenomenological, and neurobiological processes that are common and potentially disparate to these disorders. Additionally, the review will discuss four depression-related paradoxes that have emerged within the schizophrenia literature. It concludes with a brief summary of treatment considerations for patients with schizophrenia with co-morbid depressive symptoms. It is hoped that this chapter can serve as an organizing framework for future research and can help focus efforts on designing new treatments for ameliorating depression-related symptoms in patients with schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document